Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

NCT04436029 is registered in ClinicalTrials.gov with Cartesian Therapeutics as lead sponsor.

NCT NCT04436029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04436029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Lead sponsor
Cartesian Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2021
Completion date
April 9, 2022
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma